Bacopa monnieri pour Memory Loss
A Preuves Plusieurs grands essais cliniques montrent de manière constante des bénéfices significatifs.Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'braincited.com';
const params = 'ingredient\u003Dbacopa\u002Dmonnieri\u0026condition\u003Dmemory\u002Dloss';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
En conclusion
Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.
Key Study Findings
Systematic Review
Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review.
Dose: None
vs: None
Outcome: Cholinesterase inhibition and cognitive improvement
Effet: None
None
Population: In vivo animal models of AD
Other
Differential Alterations in the Expression of AMPA Receptor and Its Trafficking Proteins in the Hippocampus …
Dose: 200 mg/kg body weight
vs: Rotenone-PD mice without BME
Outcome: Recognition memory and AMPA receptor expression
Effet: None
None
Population: Rotenone-induced Parkinson's disease mouse model
Review
Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration.
Dose: None
vs: None
Outcome: Cognitive decline
Effet: None
None
Population: Alzheimer's disease patients
Other
Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma.
Dose: Bacopa monnieri (Brahmi)
vs: None
Outcome: Immunomodulatory effects in breast cancer
Effet: None
None
Population: Retracted publication - invasive ductal carcinoma
In Vitro
Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and …
Dose: Bacopa monnieri phytocompounds
vs: Standard AChE inhibitors
Outcome: AChE inhibition and neuroprotection
Effet: None
None
Population: In silico/in vitro NDD study
In Vitro
Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells.
Dose: None
vs: None
Outcome: oxidative stress markers
Effet: None
None
Population: None
Key Statistics
22
Études
1800
Participants
↑
Positive
A
Note
Referenced Papers
Brain sciences
2025
14 citations
Molecular neurobiology
2025
3 citations
Current Alzheimer research
2024
10 citations
Medical oncology (Northwood, …
2024
2 citations
Heliyon
2023
20 citations
International journal of …
2023
13 citations
The Senior care …
2021
2 citations
Scientific reports
2021
1 citations
Brain sciences
2020
72 citations
Annals of Indian …
2020
17 citations
Drug target insights
2019
103 citations
Current neuropharmacology
2019
53 citations
Epilepsy & behavior …
2018
28 citations
Journal of ethnopharmacology
2017
98 citations
PloS one
2015
51 citations
Evidence-based complementary and …
2015
14 citations
Neurochemical research
2012
85 citations
Recent patents on …
2011
132 citations
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Posologies couramment utilisées
- general:
- 300-600 mg/day standardized to 50% bacosides
- memorysupport:
- 300 mg/day for minimum 8-12 weeks
Limite supérieure : Not established; well-tolerated up to 600 mg/day in trials
Posologies étudiées dans la recherche
| Posologie | Durée | Effet | N |
|---|---|---|---|
| None | -- | Positive | -- |
| 200 mg/kg body weight | -- | Positive | -- |
| None | -- | Mixed | -- |
| Bacopa monnieri (Brahmi) | -- | Positive | -- |
| Bacopa monnieri phytocompounds | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | 72 weeks | Positive | -- |
Moment optimal de prise : With meals; effects require 8-12 weeks of consistent use
Safety & Side Effects
Effets indésirables signalés
- ⚠ Gastrointestinal discomfort (nausea, cramping, diarrhea)
- ⚠ Dry mouth
- ⚠ Fatigue in some individuals
- ⚠ Mild sedation at higher doses
Interactions connues
- ● Thyroid medications (may increase thyroid hormone levels)
- ● Anticholinergic drugs (opposes cholinergic enhancement)
- ● Sedative medications (additive CNS depression)
- ● Calcium channel blockers (may enhance blood pressure lowering)
Apport maximal tolérable : Not established; well-tolerated up to 600 mg/day in trials
Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.
Frequently Asked Questions
Does Bacopa monnieri help with Memory Loss?
Based on 22 studies with 1,800 participants, there is strong evidence from multiple clinical trials that Bacopa monnieri may support Memory Loss management. Our evidence grade is A (Strong Evidence).
How much Bacopa monnieri should I take for Memory Loss?
Studies have used various dosages. A commonly studied range is 300-600 mg/day standardized to 50% bacosides. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bacopa monnieri?
Reported side effects may include Gastrointestinal discomfort (nausea, cramping, diarrhea), Dry mouth, Fatigue in some individuals, Mild sedation at higher doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bacopa monnieri and Memory Loss?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 22 peer-reviewed studies with 1,800 total participants. The overall direction of effect is positive.
Related Evidence
Autres ingrédients pour Memory Loss
Bacopa monnieri pour d'autres pathologies
References
- [1] Maryam N ALNasser et al.. Brain Sci. 2025. Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review. doi:10.3390/brainsci15020215 PubMed
- [2] Vartika Gupta et al.. Mol Neurobiol. 2025. Differential Alterations in the Expression of AMPA Receptor and Its Trafficking Proteins in the Hippocampus Are Associated with Recognition Memory … doi:10.1007/s12035-024-04392-1 PubMed
- [3] Debasis Sen et al.. Curr Alzheimer Res. 2024. Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration. doi:10.2174/0115672050309057240404075003 PubMed
- [4] Sohini Roy et al.. Med Oncol. 2024. Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma. doi:10.1007/s12032-024-02365-x PubMed
- [5] Shehla Shoukat et al.. Heliyon. 2023. Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and in vitro research. doi:10.1016/j.heliyon.2023.e21161 PubMed
- [6] Tushar Dubey et al.. Int J Biol Macromol. 2023. Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells. doi:10.1016/j.ijbiomac.2023.123171 PubMed
- [7] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
- [8] James M Brimson et al.. Sci Rep. 2021. The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data. doi:10.1038/s41598-020-80045-2 PubMed
- [9] Jogender Mehla et al.. Brain Sci. 2020. Indian Medicinal Herbs and Formulations for Alzheimer's Disease, from Traditional Knowledge to Scientific Assessment. doi:10.3390/brainsci10120964 PubMed
- [10] Sudesh Prabhakar et al.. Ann Indian Acad Neurol. 2020. Efficacy of Bacopa Monnieri (Brahmi) and Donepezil in Alzheimer's Disease and Mild Cognitive Impairment: A Randomized Double-Blind Parallel Phase 2b … doi:10.4103/aian.AIAN_610_19 PubMed
- [11] Aimi Syamima Abdul Manap et al.. Drug Target Insights. 2019. Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical … doi:10.1177/1177392819866412 PubMed
- [12] Vini C Sekhar et al.. Curr Neuropharmacol. 2019. Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I. doi:10.2174/1570159X16666180419123022 PubMed
- [13] Amrita Mishra et al.. Epilepsy Behav. 2018. Effect of traditional medicine brahmi vati and bacoside A-rich fraction of Bacopa monnieri on acute pentylenetetrzole-induced seizures, amphetamine-induced model of … doi:10.1016/j.yebeh.2017.12.040 PubMed
- [14] Michelle D Nemetchek et al.. J Ethnopharmacol. 2017. The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain. doi:10.1016/j.jep.2016.07.073 PubMed
- [15] Surya P Pandey et al.. PLoS One. 2015. Alterations in Hippocampal Oxidative Stress, Expression of AMPA Receptor GluR2 Subunit and Associated Spatial Memory Loss by Bacopa monnieri Extract … doi:10.1371/journal.pone.0131862 PubMed
- [16] Anupama Rani et al.. Evid Based Complement Alternat Med. 2015. A Special Extract of Bacopa monnieri (CDRI-08)-Restored Memory in CoCl2-Hypoxia Mimetic Mice Is Associated with Upregulation of Fmr-1 Gene Expression … doi:10.1155/2015/347978 PubMed
- [17] Neetu Saini et al.. Neurochem Res. 2012. Neuroprotective effects of Bacopa monnieri in experimental model of dementia. doi:10.1007/s11064-012-0811-4 PubMed
- [18] G K Shinomol et al.. Recent Pat Endocr Metab Immune Drug Discov. 2011. Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy. doi:10.2174/187221411794351833 PubMed
Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.